Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $56.00.

TEM has been the subject of a number of research reports. Guggenheim initiated coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America boosted their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th.

Tempus AI Trading Up 6.6 %

Shares of NASDAQ:TEM opened at $40.76 on Tuesday. Tempus AI has a one year low of $22.89 and a one year high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a 50 day simple moving average of $48.88 and a 200 day simple moving average of $46.95.

Insider Activity at Tempus AI

In other Tempus AI news, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 845,041 shares of company stock worth $35,125,473 over the last quarter.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alphabet Inc. acquired a new stake in Tempus AI in the 2nd quarter valued at $54,289,000. Pier Capital LLC acquired a new position in shares of Tempus AI during the second quarter valued at about $2,301,000. Federated Hermes Inc. bought a new stake in shares of Tempus AI during the second quarter worth about $19,886,000. Revolution Growth Management Company Inc. acquired a new stake in shares of Tempus AI in the 2nd quarter worth about $128,133,000. Finally, Allen Operations LLC bought a new position in Tempus AI in the 2nd quarter valued at about $3,831,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.